Basic Information
| LncRNA/CircRNA Name | FTH1P3 |
| Synonyms | FTH1P3,FTHL3,FTHL3P |
| Region | GRCh38_2:27392784-27393367 |
| Ensemble | ENSG00000213453 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Flow cytometry assay, Western blot, Luciferase reporter assay, etc. |
| Sample | Human breast cancer cell lines (MCF-7,MDA-MB-231,MDA-MB-468,MDA-MB-453) and normal human breast epithelial cell (MCF-10A) were purchased from ATCC (Manassas,VA,USA). breast cancer tumorous tissue. |
| Expression Pattern | up-regulated |
| Function Description | Bioinformatics tools and luciferase reporter assay validated that,FTH1P3 promoted ABCB1 protein expression through targeting miR-206,acting as,a miRNA sponge. In summary,our results reveal the potential regulatory mechanism ,of FTH1P3 on breast cancer paclitaxel resistance through miR-206/ABCB1,providing a novel insight for the breast cancer chemoresistance. However,the occurrence of chemoresistance causes the poor prognosis,high recurrence rate and low 5-year survival rate.In the present study,we investigate the role of lncRNA FTH1P3 in breast cancer paclitaxel resistance and explore the underlying mechanism for the drug resistance generation. |
| Pubmed ID | 29971911 |
| Year | 2018 |
| Title | Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. |
External Links
| Links for FTH1P3 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |